Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Akebia closes $41mm Series C to advance lead anemia candidate into Phase III

Executive Summary

Akebia Therapeutics Inc. (treatments for anemia and vascular diseases) raised $41mm through its Series C round that was co-led by Satter Investment Management and Novo AS. Existing investors Novartis Venture Funds, Kearny Venture Partners, Venture Investors LLC, Athenian Venture Partners, Triathlon Medical Ventures, AgeChem Venture, and Sigvion Capital Fund also participated. Akebia plans to use the proceeds to prepare its lead drug candidate AKB6548--currently in Phase IIb for anemia secondary to chronic kidney disease--for Phase III trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies